Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Court Finds United Therapeutics' Interference With Launch of Generic Treprostinil Injection Caused Losses Of More Than $137M
Liquidia Corporation (NASDAQ:LQDA) (Liquidia), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, announced today that the United States District Court for the District of New Jersey (District Court) has found that the interference by United Therapeutics Corporation (United Therapeutics) with the launch of generic Treprostinil Injection caused losses in excess of $137M. Treprostinil Injection is manufactured by Sandoz Inc. (Sandoz) and was launched as the first-to-file, fully-substitutable generic treprostinil for parenteral administration in March 2019. Liquidia PAH, LLC (formerly known as RareGen), a wholly owned subsidiary of Liquidia (Liquidia PAH), partnered with Sandoz in August 2018 on an exclusive basis to market and commercialize Treprostinil Injection.
为罕见心肺疾病患者开发创新疗法的生物制药公司Liquidia Corporation（纳斯达克股票代码：LQDA）（Liquidia）今天宣布，美国新泽西地区地方法院（地方法院）认定，联合疗法公司（United Therapeutics）干预仿制药的推出造成了超过1.37亿美元的损失。曲前列斯尼注射液由山德士公司（Sandoz）制造，于2019年3月作为首款完全可替代的肠胃外给药仿制曲前列斯尼上市。Liquidia（Liquidia PAH）的全资子公司Liquidia PAH, LLC（前身为RareGen）于2018年8月与山德士合作，独家销售和商业化了曲普司尼注射液。